高洪元

[摘要] 目的 探討平之膠囊對缺血性中風患者神經元特異性烯醇化酶(NSE)、S100B及丙二醛(MDA)影響。方法 方便選取該院2018年6月—2019年6月收治的200例缺血性中風患者納入研究,通過交替分組法分為對照組與觀察組,每組100例,對照組采用常規治療,觀察組常規治療+平之膠囊,分析兩組患者綜合治療效果,治療前后NSE、S100B及MDA,治療后的NIHSS評分和BI評分。結果 觀察組治療有效率(89.00%)高于對照組(78.00%),數據差異有統計學意義(χ2=4.319, P<0.05);治療后觀察組患者NSE[(8.03±0.08)pg/L]、S100B[(0.64±0.08)pg/L]及MDA[(6.68±0.86)nmol/L]明顯低于對照組,差異有統計學意義(t=73.391、21.619、14.788,P<0.05);觀察組患者NIHSS評分[(5.14±0.95)分]小于對照組,差異有統計學意義(t=15.901,P<0.05),BI評分(78.82±3.15)分大于對照組,差異有統計學意義(t=25.121,P<0.05)。結論 缺血性中風患者常規治療同時增加平之膠囊,可有效降低NSE、S100B及MDA,改善神經功能,提高生活質量,值得推廣與應用。
[關鍵詞] 平之膠囊;缺血性中風;NSE;S100B;MDA;NIHSS;生活質量
[中圖分類號] R5? ? ? ? ? [文獻標識碼] A? ? ? ? ? [文章編號] 1674-0742(2020)07(c)-0098-04
[Abstract] Objective To investigate the effect of Pingzhi capsule on neuron-specific enolase (NSE), S100B and malondialdehyde (MDA) in patients with ischemic stroke. Methods Convenient selection 200 patients with ischemic stroke admitted to the hospital from June 2018 to June 2019 were included in the study. They were divided into a control group and an observation group by alternate grouping. Each group had 100 patients. Conventional treatment + Pingzhi capsule, analyze the comprehensive treatment effect of the two groups of patients, NSE, S100B and MDA before and after treatment, NIHSS score and BI score after treatment. Results The treatment efficiency of the observation group (89.00%) was higher than that of the control group (78.00%), and the data were significantly different (χ2=4.319, P<0.05); NSE [(8.03±0.08) pg/L], S100B [(0.64±0.08) pg/L] and MDA [(6.68±0.86) nmol/L] were significantly lower than the control group, the difference was statistically significant(t=73.391, 21.619, 14.788, P<0.05); observation group of the NIHSS score of the patients [(5.14±0.95) points] was less than the control group, the difference was statistically significant(t=15.901, P<0.05), the BI score (78.82±3.15)points was greater than the control group, the difference was statistically significant (t=25.121, P<0.05). Conclusion The routine treatment of patients with ischemic stroke and the addition of Pingzhi capsule can effectively reduce NSE, S100B and MDA, improve nerve function, and improve the quality of life, which is worthy of popularization and application.
[Key words] Pingzhi capsule; Ischemic stroke; NSE; S100B; MDA; NIHSS; Quality of life
缺血性中風是腦卒中的主要類型,結合臨床文獻分析,隨著高血壓、糖尿病、高脂血癥等發病率的提高,缺血性中風發病率進一步提高,且具有較高的致殘率、致死率[1]。統計學數據資料證實,缺血性中風在整個急性腦血管病中占到75.00%以上,通過對缺血性中風的治療研究與分析,能夠為提高缺血性中風的治療效果提供依據[2]。相關研究證實NSE、S100B、MDA均能夠反映出患者的腦部損傷程度,通過對上述物質的變化可間接評估患者腦部損傷情況,同時也是預測患者預后的重要指標[3]。中醫藥技術的發展為缺血性中風治療提供了更多思路,該文方便選擇該院2018年6月—2019年6月收治的200例缺血性中風患者作為研究對象,探討平之膠囊在缺血性中風治療中的應用效果以及對NSE、S100B及MDA的影響,結合研究結果指導臨床缺血性中風的有效治療,現報道如下。
祝美珍等[9],研究指出,經治療,對照組患者治療有效率為76.7%,而治療組患者治療有效率為90.0%。該研究中,觀察組患者實施常規治療+平之膠囊治療,其治療有效率為89.00%,明顯高于對照組的78.00%。祝美珍等人研究雖然與該文所使用的藥方不同,但是總體藥物作用機制較為接近,同樣證實了中藥使用可降低NSE、S100B,同該文研究結果較為接近。
綜上所述,缺血性中風患者常規治療同時增加平之膠囊,可有效降低NSE、S100B及MDA,改善神經功能,提高生活質量。
[參考文獻]
[1]? 張婷,安琪.腦心通膠囊聯合穴位埋線治療缺血性腦中風痰熱腑實證療效及對血液流變性影響的研究[J].陜西中醫,2018,39(12):1684-1686.
[2]? 李薇,魏毅.血塞通軟膠囊聯合阿托伐他汀應用于急性缺血性中風患者的療效觀察[J].中南醫學科學雜志,2018,46(4):405-407.
[3]? 黃國恩.蛭龍活血通瘀膠囊結合辨證治療缺血性中風急性期觀察[J].光明中醫,2018,33(3):360-362.
[4]? 趙春蘭.抗粘降脂丸配合通栓膠囊治療缺血性中風急性期患者的藥物研究[J].中國現代藥物應用,2018,12(10):195-196.
[5]? CHEN Shu-qi,CAI De-chun,CHEN Ji-xin,et al.Altered Brain Regional Homogeneity Following Contralateral Acupuncture at Quchi (LI 11) and Zusanli (ST 36) in Ischemic Stroke Patients with Left Hemiplegia: An fMRI Study[J].Chinese Journal of Integrative Medicine,2020,26(1):20-25.
[6]? Fitzgerald Seán,Wang Shunli,Dai Daying,et al.Orbit image analysis machine learning software can be used for the histological quantification of acute ischemic stroke blood clots.[J]. PloS one,2019,14(12):225-231.
[7]? Sherban Adi,Armon Carmel,Rapoport Micha.Treatment with dual antiplatelet therapy for secondary prevention of stroke - pros and cons [J]. Harefuah,2018,157(12):773-778.
[8]? 陳慧亭,崔應麟.康益膠囊治療氣虛血瘀型缺血性中風恢復期的臨床觀察[J].中醫藥通報,2018,17(2):48-50.
[9]? 祝美珍,羅劉軍,武麗,等.清腦益元湯治療缺血性中風臨床療效及對NSE、S100B表達的影響[J].中華中醫藥雜志,2019, 34(2):854-857.
(收稿日期:2020-04-26)